title: Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.
authors.forename: R G
authors.initials: RG
authors.lastname: Piazza
authors.forename: V
authors.initials: V
authors.lastname: Magistroni
authors.forename: F
authors.initials: F
authors.lastname: Andreoni
authors.forename: A
authors.initials: A
authors.lastname: Franceschino
authors.forename: L
authors.initials: L
authors.lastname: Tornaghi
authors.forename: M
authors.initials: M
authors.lastname: Varella-Garcia
authors.forename: S
authors.initials: S
authors.lastname: Bungaro
authors.forename: F
authors.initials: F
authors.lastname: Colnaghi
authors.forename: G
authors.initials: G
authors.lastname: Corneo
authors.forename: E M
authors.initials: EM
authors.lastname: Pogliani
authors.forename: C
authors.initials: C
authors.lastname: Gambacorti-Passerini
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate